References
[1] ROSENSON R S, BAKER S K, JACOBSON T A, et al. An assessment by
the Statin Muscle Safety Task Force: 2014 update [J]. Journal of
clinical lipidology, 2014, 8(3 Suppl): S58-71.
[2] KODADEK L, CARMICHAEL II S P, SESHADRI A, et al. Rhabdomyolysis:
an American Association for the Surgery of Trauma Critical Care
Committee Clinical Consensus Document [J]. Trauma Surg Acute Care
Open, 2022, 7(1): e000836.
[3] MCMAHON G M, ZENG X, WAIKAR S S. A risk prediction score for
kidney failure or mortality in rhabdomyolysis [J]. JAMA Intern Med,
2013, 173(19): 1821-8.
[4] NEWMAN C B, PREISS D, TOBERT J A, et al. Statin Safety and
Associated Adverse Events: A Scientific Statement From the American
Heart Association [J]. Arteriosclerosis, thrombosis, and vascular
biology, 2019, 39(2): e38-e81.
[5] KELLICK K A, BOTTORFF M, TOTH P P, et al. A clinician’s guide to
statin drug-drug interactions [J]. Journal of clinical lipidology,
2014, 8(3 Suppl): S30-46.
[6] JANSSEN L, ALLARD N A E, SARIS C G J, et al. Muscle Toxicity of
Drugs: When Drugs Turn Physiology into Pathophysiology [J]. Physiol
Rev, 2020, 100(2): 633-72.
[7] ZHAO A, GUO D, ZHU M, et al. Analysis of 1 702 cases of
drug-associated muscle adverse reactions [J]. Chin J Clin
Pharmacol, 2023, 39(16): 2393-6.
[8] ZHAO A, GUO D, ZHU M, et al. Establishment and optimization of a
module for automatic monitoring drug-associated muscle adverse reactions
based on HIS [J]. Chin J Drug Appl Mon, 2023, 20(3): 176-9,210.
[9] YAO C, LIU D, GUO D, et al. The development on active
surveillance and assessment system-Ⅱ of adverse drug events [J].
Chin J Drug Appl Mon, 2020, 17(06): 387-91.
[10] KYRIAKIDES T, ANGELINI C, SCHAEFER J, et al. EFNS guidelines on
the diagnostic approach to pauci- or asymptomatic hyperCKemia [J].
Eur J Neurol, 2010, 17(6): 767-73.
[11] GABOW P A, KAEHNY W D, KELLEHER S P. The spectrum of
rhabdomyolysis [J]. Medicine, 1982, 61(3): 141-52.
[12] NARANJO C A, BUSTO U, SELLERS E M, et al. A method for
estimating the probability of adverse drug reactions [J]. Clin
Pharmacol Ther, 1981, 30(2): 239-45.
[13] DAI-HONG G, CHENG-XUAN Y. Expert consensus on automated
surveillance and evaluation of clinical medication risk based on
hospital information system data [J]. Chin J Drug Appl Mon, 2021,
18(05): 277-87.
[14] DUGUé A, BAGHERI H, LAPEYRE-MESTRE M, et al. Detection and
incidence of muscular adverse drug reactions: a prospective analysis
from laboratory signals [J]. European journal of clinical
pharmacology, 2004, 60(4): 285-92.
[15] MELLI G, CHAUDHRY V, CORNBLATH D R. Rhabdomyolysis: an
evaluation of 475 hospitalized patients [J]. Medicine, 2005, 84(6):
377-85.
[16] GRIGORIAN A, GABRIEL V, NGUYEN N T, et al. Black Race and Body
Mass Index Are Risk Factors for Rhabdomyolysis and Acute Kidney Injury
in Trauma [J]. Journal of investigative surgery : the official
journal of the Academy of Surgical Research, 2020, 33(3): 283-90.
[17] PEDRO-BOTET J, MILLáN NúñEZ-CORTéS J, CHILLARóN J J, et al.
Severity of statin-induced adverse effects on muscle and associated
conditions: data from the DAMA study [J]. Expert opinion on drug
safety, 2016, 15(12): 1583-7.
[18] OSTROWSKI P, BONCZAR M, AVRAM A E, et al. Safety monitoring of
drug-induced muscle injury and rhabdomyolysis: a biomarker-guided
approach for clinical practice and drug trials [J]. Clinical
chemistry and laboratory medicine, 2023, 61(10): 1688-99.
[19] GAO Z, LIANG Y, WU Z, et al. Prevalence of Rhabdomyolysis
Following Bariatric Surgery and its Associated Risk Factors: a
Meta-Analysis [J]. Obesity surgery, 2023, 33(4): 990-1003.
[20] LAGANDRé S, ARNALSTEEN L, VALLET B, et al. Predictive factors
for rhabdomyolysis after bariatric surgery [J]. Obesity surgery,
2006, 16(10): 1365-70.
[21] JONES J D, KIRSCH H L, WORTMANN R L, et al. The causes of
drug-induced muscle toxicity [J]. Curr Opin Rheumatol, 2014, 26(6):
697-703.
[22] CONFORTI A, CHIAMULERA C, MORETTI U, et al. Musculoskeletal
adverse drug reactions: a review of literature and data from ADR
spontaneous reporting databases [J]. Current drug safety, 2007,
2(1): 47-63.
[23] CARROLL M W, CHOI H, MIN S, et al. Rhabdomyolysis in a patient
treated with linezolid for extensively drug-resistant tuberculosis
[J]. Clinical infectious diseases : an official publication of the
Infectious Diseases Society of America, 2012, 54(11): 1624-7.
[24] VINCI P, PANIZON E, TOSONI L M, et al. Statin-Associated
Myopathy: Emphasis on Mechanisms and Targeted Therapy [J]. Int J Mol
Sci, 2021, 22(21).
[25] OCHS-BALCOM H M, NGUYEN L M, MA C, et al. Clinical features
related to statin-associated muscle symptoms [J]. Muscle & nerve,
2019, 59(5): 537-43.
[26] WARDEN B A, GUYTON J R, KOVACS A C, et al. Assessment and
management of statin-associated muscle symptoms (SAMS): A clinical
perspective from the National Lipid Association [J]. Journal of
clinical lipidology, 2023, 17(1): 19-39.
[27] LU H, COLE S R, HOWE C J, et al. Toward a Clearer Definition of
Selection Bias When Estimating Causal Effects [J]. Epidemiology
(Cambridge, Mass), 2022, 33(5): 699-706.